Firazyr (Icatibant Injection) Approved For Acute Attacks Of Hereditary Angioedema, USA
Firazyr (icatibant injection) has been approved by the FDA for acute attacks of hereditary angioedema in adults aged 18+ years. Icatibant is a potent and selective bradykinin B2 receptor antagonist - it inhibits the effects of bradykinin, which is thought to cause HAE (hereditary angioedema) symptoms of inflammation, pain and localized swelling; it treats the clinical symptoms of an acute attack ...

Biotech Calendar: 2011-12 FDA Drug Approvals
An updated list of drug and biotech firms with drug approvals expected through the first quarter 2012. Click to view a price quote on INCY . Click to research the Drugs industry.